AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10070909 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 24
Study 7670785 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis education programme
Number of subjects: 0
Study 7670785 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 1963125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-soluble-fibre diet (5 g guar gum thrice daily)
Number of subjects: 11
Study 1963125 — intervention group
Group type: COMPARATOR
Intervention: High-glucose diet (500 ml glucose drink providing 100 g glucose per day)
Number of subjects: 11
Study 6450789 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 21
Study 6450789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31174239 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with vincristine, dactinomycin, and cyclophosphamide (VAC) or VAC alternating with vincristine and irinotecan, with early radiation therapy (RT) at week 4 concurrent with irinotecan in the experimental arm.
Number of subjects: 424
Study 29112051 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric Training (PLT)
Number of subjects: 30
Study 29112051 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (SRT)
Number of subjects: 30
Study 29112051 — intervention group
Group type: COMPARATOR
Intervention: Control (CNT)
Number of subjects: 30
Study 26553448 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM SLIT tablet 6 SQ HDM
Number of subjects: 195
Study 26553448 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM SLIT tablet 12 SQ HDM
Number of subjects: 195
Study 26553448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 24127416 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg
Number of subjects: 0
Study 24127416 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg
Number of subjects: 0
Study 24127416 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 22051246 — intervention group
Group type: EXPERIMENTAL
Intervention: SFM ‐ Sensodyne Fresh Mint(®) RDA 70
Number of subjects: 28
Study 22051246 — intervention group
Group type: COMPARATOR
Intervention: CPHM ‐ Crest Pro‐Health Clean Mint(®) RDA 120
Number of subjects: 28
Study 19544556 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic writing task
Number of subjects: 80
Study 19544556 — intervention group
Group type: COMPARATOR
Intervention: Control writing task
Number of subjects: 80
Study 17513690 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly automated telephone disease management (ATDM)
Number of subjects: 0
Study 17513690 — intervention group
Group type: COMPARATOR
Intervention: Monthly group medical visits
Number of subjects: 0
Study 16243128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 6 mg/kg per day for 3 weeks followed by 3 weeks of placebo
Number of subjects: 0
Study 16243128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 6 mg/kg per day for 6 weeks
Number of subjects: 0
Study 16243128 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin 11 mg/kg per day for 6 weeks
Number of subjects: 0
Study 14598620 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine and i.v. clonidine 1 microgram.kg‐1 (CLO group)
Number of subjects: 40
Study 14598620 — intervention group
Group type: COMPARATOR
Intervention: Overlay alone and normal saline (CTL group)
Number of subjects: 40
Study 10766467 — intervention group
Group type: EXPERIMENTAL
Intervention: C+E (5 mg x kg(‐1) caffeine and 1 mg x kg(‐1) ephedrine)
Number of subjects: 12
Study 10766467 — intervention group
Group type: EXPERIMENTAL
Intervention: C+E (4 mg x kg(‐1) caffeine and 1 mg x kg(‐1) ephedrine)
Number of subjects: 12
Study 10766467 — intervention group
Group type: EXPERIMENTAL
Intervention: C+E (4 mg x kg(‐1) caffeine and 0.8 mg x kg(‐1) ephedrine)
Number of subjects: 12
Study 10766467 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study 10766467 — intervention group
Group type: EXPERIMENTAL
Intervention: C+E (lowest dose: 4 mg x kg(‐1) caffeine and 0.8 mg x kg(‐1) ephedrine)
Number of subjects: 12
Study 10766467 — intervention group
Group type: EXPERIMENTAL
Intervention: C+E (all doses)
Number of subjects: 12
Study 8829061 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary tract infection (UTI) during pregnancy
Number of subjects: 2641
Study 8829061 — intervention group
Group type: EXPERIMENTAL
Intervention: Primiparity
Number of subjects: 2641
Study 8829061 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 2641
Study 8829061 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than a high school education
Number of subjects: 2641
Study 8829061 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to diethylstilbestrol in utero
Number of subjects: 2641
Study 8829061 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (kg/m2) > 30
Number of subjects: 2641
Study 8829061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 2641
Study 8829061 — intervention group
Group type: EXPERIMENTAL
Intervention: Primiparas with UTI during pregnancy
Number of subjects: 2641
Study 1481117 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy (55.3 Gy within 17 consecutive days)
Number of subjects: 23
Study 1481117 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy combined with chemotherapy (20 mg mitomycin C/m2 on day 5)
Number of subjects: 23
Study 1481117 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy
Number of subjects: 23
Study 3549876 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 3549876 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 29876577 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and regular breast milk expression using an electric double-breast pump
Number of subjects: 60
Study 29876577 — intervention group
Group type: COMPARATOR
Intervention: Direct breastfeeding without regular pump expression (Control)
Number of subjects: 60
Study 29876577 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and regular breast milk expression
Number of subjects: 60
Study 29381191 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) at a starting dose of 1.8 mg/m2/cycle (0.8 mg/m2 on day 1 and 0.5 mg/m2 on days 8 and 15 of a 21- to 28-day cycle, ≤6 cycles)
Number of subjects: 326
Study 29381191 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 326
Study 26540448 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration+Instruction
Number of subjects: 100
Study 26540448 — intervention group
Group type: COMPARATOR
Intervention: Taught Method Only
Number of subjects: 100
Study 24475826 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib mesylate for 1 and 3 years
Number of subjects: 0
Study 24475826 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazard-adjusted follow-up schedules
Number of subjects: 0
Study 24475826 — intervention group
Group type: COMPARATOR
Intervention: NCCN guidelines for imaging with CT
Number of subjects: 0
Study 22578498 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (low dose)
Number of subjects: 0
Study 22578498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20457538 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological participants with spasticity (identified by Ashworth score ≥1)
Number of subjects: 87
Study 20457538 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 87
Study 20457538 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke group
Number of subjects: 87
Study 20457538 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with hypertonia in the plantar flexors
Number of subjects: 87
Study 20457538 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized reflex torque
Number of subjects: 87
Study 17653020 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (300 mg IV over 30 min, then 20 mg/kg/24 h if needed)
Number of subjects: 223
Study 17653020 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide (1 gm IV bolus, then 2 mg/min for 24 h if needed)
Number of subjects: 223
Study 17653020 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 223
Study 17653020 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 223
Study 15760627 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 81
Study 15760627 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide
Number of subjects: 81
Study 12081124 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple dye
Number of subjects: 427
Study 12081124 — intervention group
Group type: COMPARATOR
Intervention: 70% Alcohol
Number of subjects: 427
Study 10443734 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant LHRH analogue treatment (n = 50)
Number of subjects: 111
Study 10443734 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (n = 53)
Number of subjects: 111
Study 7878758 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-day cyclosporine (CsA) dosing
Number of subjects: 8
Study 7878758 — intervention group
Group type: COMPARATOR
Intervention: b.i.d. cyclosporine (CsA) dosing
Number of subjects: 8
Study 2160312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, etoposide, and ifosfamide (PEI)
Number of subjects: 78
Study 2160312 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and etoposide (PE)
Number of subjects: 78
Study 466592 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (120 mg) given orally at weekly intervals for 1 month, every 2 weeks up to 3 months, then every 3 months until 18 months
Number of subjects: 308
Study 466592 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 308
Study 466592 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (120 mg) given orally
Number of subjects: 308
Study 31744331 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 0
Study 31744331 — intervention group
Group type: COMPARATOR
Intervention: Sham ablation (potential control group)
Number of subjects: 0
Study 30704504 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial pulsed electromagnetic fields (T-PEMF) treatment (30 min/day, 50 Hz, ±50 V, 3 ms squared pulses) for 8 weeks
Number of subjects: 50
Study 30704504 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (sham stimulation, 30 min/day) for 8 weeks
Number of subjects: 50
Study 30704504 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial pulsed electromagnetic fields (T-PEMF) treatment
Number of subjects: 50
Study 28435032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systematic dietary manipulation (ISDM) for 1 year
Number of subjects: 0
Study 28435032 — intervention group
Group type: COMPARATOR
Intervention: Non-intensive group (control)
Number of subjects: 0
Study 25518956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive tracing efforts initiated after 1686 mother-infant pairs were enrolled, targeting those lost to follow-up.
Number of subjects: 2369
Study 25518956 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support including a family maize supplement provided to participants.
Number of subjects: 2369
Study 25518956 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal hemoglobin and older maternal age.
Number of subjects: 2369
Study 25518956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive tracing efforts to locate lost participants.
Number of subjects: 2369
Study 24848627 — intervention group
Group type: EXPERIMENTAL
Intervention: FR+active (high physical activity, >12,000 steps/day)
Number of subjects: 22
Study 24848627 — intervention group
Group type: COMPARATOR
Intervention: FR+inactive (low physical activity, <4500 steps/day)
Number of subjects: 22
Study 22307831 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN treatment
Number of subjects: 214
Study 22307831 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of WT virus at baseline
Number of subjects: 214
Study 19391540 — intervention group
Group type: EXPERIMENTAL
Intervention: Prozac capsule, 20 mg/d
Number of subjects: 75
Study 19391540 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture for 30-40 min, needle retained for 1 h, once daily
Number of subjects: 75
Study 19391540 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Prozac and electroacupuncture
Number of subjects: 75
Study 19391540 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 75
Study 17498019 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sevoflurane
Number of subjects: 20
Study 17498019 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% desflurane
Number of subjects: 20
Study 15266166 — intervention group
Group type: EXPERIMENTAL
Intervention: Care program from the Disease Management project
Number of subjects: 400
Study 15266166 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrive study (not specified as intervention)
Number of subjects: 400
Study 12019085 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg i.v. once daily followed by oral 400 mg for 7 to 14 days)
Number of subjects: 628
Study 12019085 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav (1.2 g i.v. three times a day followed by oral 625 mg three times a day, with or without clarithromycin)
Number of subjects: 628
Study 9814396 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine-phenylephrine (Prilophen)
Number of subjects: 40
Study 9814396 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine infiltration
Number of subjects: 40
Study 7714934 — intervention group
Group type: EXPERIMENTAL
Intervention: String test for detection of SBBO
Number of subjects: 15
Study 7714934 — intervention group
Group type: COMPARATOR
Intervention: Sterile endoscopic method for sampling small bowel secretions
Number of subjects: 15
Study 2630348 — intervention group
Group type: EXPERIMENTAL
Intervention: Biometry
Number of subjects: 0
Study 2630348 — intervention group
Group type: COMPARATOR
Intervention: No Biometry
Number of subjects: 0
Study 7298924 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride (5% solution)
Number of subjects: 40
Study 7298924 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride (5% solution)
Number of subjects: 40
Study 7298924 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (5% solution)
Number of subjects: 40
Study 7298924 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 40
Study 30988479 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance information about one of two randomly selected monetary prizes
Number of subjects: 257
Study 30988479 — intervention group
Group type: COMPARATOR
Intervention: Theoretical models describing curiosity as a desire to learn about total rewards
Number of subjects: 257
Study 30988479 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended model allowing for attribute-specific anticipatory utility
Number of subjects: 257
Study 28316011 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking training combined with vitamin D supplementation for 12 weeks in MVD group
Number of subjects: 27
Study 28316011 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking training combined with vitamin D supplementation for 12 weeks in LVD group
Number of subjects: 27
Study 28316011 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking training combined with vitamin D supplementation for 12 weeks in both groups
Number of subjects: 27
Study 25689529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole lock solution (10 mg/ml cotrimoxazole and 2500 U/ml heparin)
Number of subjects: 0
Study 25689529 — intervention group
Group type: COMPARATOR
Intervention: Heparin (2500 U/ml)
Number of subjects: 0
Study 23134549 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 polyunsaturated fatty acids (PUFAs) (3 g, 12 h before PCI) plus standard treatment (n = 43)
Number of subjects: 90
Study 23134549 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group) (n = 47)
Number of subjects: 90
Study 23134549 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 90
Study 21878093 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P
Number of subjects: 2
Study 21878093 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual
Number of subjects: 2
Study 19698909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-linked UHMWPE liner
Number of subjects: 45
Study 19698909 — intervention group
Group type: COMPARATOR
Intervention: Conventional UHMWPE liner
Number of subjects: 45
Study 18202577 — intervention group
Group type: EXPERIMENTAL
Intervention: OCC (occlusive training group)
Number of subjects: 15
Study 18202577 — intervention group
Group type: COMPARATOR
Intervention: NOR (normal training group)
Number of subjects: 15
Study 15037560 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 5429
Study 15037560 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based treatment
Number of subjects: 5429
Study 11146078 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin-based chemotherapy (IPCT) 100 mg/m²
Number of subjects: 132
Study 11146078 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cisplatin-based chemotherapy (IVCT) 50 mg/m²
Number of subjects: 132
Study 9263559 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TNF-alpha levels in infants with sepsis
Number of subjects: 49
Study 9263559 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 49
Study 8282275 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium L‐glutamate (MSG) doses of 1.5, 3.0 and 3.15 g/person
Number of subjects: 71
Study 8282275 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 71
Study 3552456 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic lignocaine (5%) spray
Number of subjects: 72
Study 3552456 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous lignocaine (5%) spray
Number of subjects: 72
Study 3552456 — intervention group
Group type: COMPARATOR
Intervention: Aqueous cinchocaine (2%) spray
Number of subjects: 72
Study 11476655 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy (IRT)
Number of subjects: 168
Study 11476655 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 168
Study 31846915 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoid microbial colonization analysis using 16S rRNA pyrosequencing
Number of subjects: 32
Study 31846915 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without OME)
Number of subjects: 32
Study 31846915 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxonomic analysis of microbiota distribution
Number of subjects: 32
Study 31846915 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted UniFrac distances analysis
Number of subjects: 32
Study 29286865 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) with corticosteroids in a fixed tapering regime
Number of subjects: 25
Study 29286865 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids only (Control)
Number of subjects: 25
Study 26717501 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor training
Number of subjects: 150
Study 26717501 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentoring
Number of subjects: 150
Study 26717501 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor training and peer mentoring combined
Number of subjects: 150
Study 26717501 — intervention group
Group type: COMPARATOR
Intervention: Control/usual practice
Number of subjects: 150
Study 24097374 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 32
Study 22118412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 70
Study 22118412 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic parameters (LVSV, LVSI, LVFS, RVd, VPMR, PISA)
Number of subjects: 70
Study 22118412 — intervention group
Group type: EXPERIMENTAL
Intervention: LVSI
Number of subjects: 70
Study 22118412 — intervention group
Group type: EXPERIMENTAL
Intervention: LVFS
Number of subjects: 70
Study 19950239 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin‐beta 30,000 U administered s.c. q.w. (group A)
Number of subjects: 42
Study 19950239 — intervention group
Group type: COMPARATOR
Intervention: Reduced ribavirin dose of 600 mg daily (group B)
Number of subjects: 42
Study 17269908 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in brief tobacco cessation interventions (BI)
Number of subjects: 910
Study 16190792 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (daily dose range between 25 and 100 mg)
Number of subjects: 28
Study 16190792 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (matched for age and IQ); n = 28
Number of subjects: 28
Study 12105139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified cardiovascular risk management after 6 months (n=53)
Number of subjects: 382
Study 12105139 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with target organ damage (TOD)
Number of subjects: 382
Study 12105139 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 382
Study 10591428 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional phototherapy (special blue light)
Number of subjects: 108
Study 10591428 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic phototherapy
Number of subjects: 108
Study 7491646 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of dextroamphetamine orally every fourth day for 10 sessions paired with physical therapy
Number of subjects: 10
Study 7491646 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally every fourth day for 10 sessions paired with physical therapy
Number of subjects: 10
Study 1976487 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms via MDI
Number of subjects: 16
Study 1976487 — intervention group
Group type: COMPARATOR
Intervention: Albuterol 200 micrograms via MDI
Number of subjects: 16